INTRODUCTION
============

Decreased physical function is a representative sign of frailty in elderly people \[[@B1]\], which is usually accompanied by a decrease in testosterone levels in elderly men \[[@B2]\]. Lower testosterone levels are associated with decreased physical function and increased mortality \[[@B3]\], and frailty is associated with decreased quality of life \[[@B4]\]. However, there is no effective clinical treatment to restore physical function in the elderly. One of the mechanisms for the decreased physical function in the elderly is sarcopenia \[[@B5]\], and especially in elderly men, muscle mass is associated with testosterone levels \[[@B6]\].

Although many randomized controlled trials (RCTs) of testosterone replacement therapy (TRT) have been performed, these studies generally had small sample sizes and a variety of study designs, and the effects of TRT on improving physical function are equivocal \[[@B7][@B8][@B9]\]. While in one study \[[@B7]\] testosterone supplementation improved strength and was suggested to have a role in the treatment of frailty in hypogonadic males, another study \[[@B8]\] did not observe any increase in muscle strength, but only an increase in muscle mass.

Some systematic reviews (SRs) \[[@B10][@B11][@B12][@B13]\] investigating the effects of TRT on the body have been published. However, one study \[[@B10]\] included middle-aged subjects and did not include recent studies. Although another study \[[@B13]\] performed a comprehensive SR including elderly men, the heterogeneity in the target groups and outcomes was large, and no significant conclusions were suggested. Accordingly, a quantitative analysis including recently published high-quality RCTs assessing physical function \[[@B2][@B14]\] could yield additional clinical significance. Therefore, we conducted a rapid SRs, including elderly men receiving TRT, to assess the effects of TRT on muscle strength and physical function. We also performed quantitative analyses of the outcomes of some RCTs in order to determine their clinical significance. The search strategies and study selection criteria are explained at the end.

TESTOSTERONE REPLACEMENT THERAPY AND MUSCLE STRENGTH
====================================================

Muscle strength is commonly measured with hand grip strength and the 1-repetition maximum (1-RM) for exercises performed as part of strength testing. Sixteen studies examined the effects of testosterone supplementation on muscle strength. Fourteen studies assessed muscle strength as a primary outcome and 2 as a secondary outcome. The other primary and secondary outcomes investigated in each of the studies are listed in [Table 1](#T1){ref-type="table"} \[[@B2][@B7][@B8][@B9][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27]\]. The most common measurements for muscle strength were hand grip strength and leg muscle strength (knee extension and flexion). Other measurements included single or double leg press, chest press, and triceps extension.

1. Hand grip
------------

Ten studies included in the analysis measured muscle strength in terms of hand grip strength. Five of these studies were conducted in the United States, 2 in the United Kingdom, 1 in the Netherlands, 1 in Australia, and 1 in New Zealand. A total of 1002 participants were included in the analysis. The intervention period varied from 8 weeks to 1 year. All hand grip strength measurements were expressed in kilograms, except for one study \[[@B15]\], for which a pound-to-kilogram conversion was done for the purposes of our analysis. The overall results ([Fig. 1](#F1){ref-type="fig"}) showed that TRT does not increase hand grip strength. However, individual studies, such as a randomized, placebo-controlled, doubleblind study \[[@B15]\], have found that hand grip strength improved after testosterone administration. Other studies \[[@B7][@B26]\] that showed improved hand grip strength after testosterone supplementation could not be included in the analysis because they only presented data in figures.

2. Leg muscle strength
----------------------

Seven studies included in the analysis measured leg muscle strength. All 7 studies included information for the knee extensor muscles, consisting of a total of 780 participants. Three studies were conducted in the United States, 2 in the United Kingdom, 1 in New Zealand, and 1 in the Netherlands. The study conducted in the Netherlands \[[@B20]\] did not include measurements for the knee flexor muscles, so only 6 of the 7 studies included for the knee extensor analysis were included in the analysis of knee flexor strength. This resulted in a total of 543 participants for the knee flexor analysis. The intervention period varied from 12 weeks to 1 year. Lower muscle strength measurements were expressed as 1-RM in kilograms, newton-meters per second, or watts. Although marginal effects were shown for increased knee extensor strength ([Fig. 2](#F2){ref-type="fig"}), when combined with the outcomes for knee flexor strength, the overall results showed no significant difference.

TESTOSTERONE REPLACEMENT THERAPY AND PHYSICAL FUNCTION
======================================================

Physical function was commonly measured by the 6-minute walk test \[[@B28]\], the Physical Activity Scale for the Elderly (PASE) questionnaire \[[@B29]\], the physical-function domain (PF-10) of the Medical Outcomes Study 36-Item Short-Form Health Survey \[[@B30]\], a physical performance test (PPT) \[[@B31]\], and the Short Physical Performance Battery (ability to rise from a chair, static balance, and 8-foot walk) \[[@B32]\]. Other tests performed in some studies that were not included in our analyses included the supine-to-stand test \[[@B33]\], and the Get-Up- and-Go test \[[@B34]\].

1. 6-minute walk test
---------------------

Three studies included in the analysis showed results of the 6-minute walk test. Two of these studies were conducted in the United States, and 1 in New Zealand. A total of 733 participants were included in the analysis. The intervention period varied from 6 months to 1 year. All TRT interventions were done using transdermal testosterone gel, although the dosages differed between studies. The overall results ([Fig. 3](#F3){ref-type="fig"}) showed that TRT improved the 6-minute walking distance by 9.35 m (95% confidence interval \[CI\], 0.64--18.07 m).

2. Physical Activity Scale for the Elderly score
------------------------------------------------

Three studies included results from the PASE questionnaire \[[@B23][@B24][@B27]\], which is known to be a reliable instrument for assessing physical activity in older people \[[@B29]\]. Two studies were conducted in the United States, and 1 was conducted in New Zealand. A total of 504 participants were included in the analysis. The intervention period varied from 6 months to 1 year, and the participants in all 3 studies received transdermal testosterone supplementation. Two studies \[[@B23][@B24]\] administered 5 mg per day for 12 months, while another \[[@B27]\] administered 50 mg per day for 6 months. Even though each of the individual studies did not show statistically significant improvements in the PASE score, when the individual results were combined, the overall results ([Fig. 4](#F4){ref-type="fig"}) showed that there was an increase of 18.22 points (95% CI, 1.27--35.18 points) in the PASE score with TRT.

3. Physical performance test
----------------------------

Three studies were combined to analyze the effects of TRT on physical performance. Two studies were conducted in the United States, and 1 was conducted in New Zealand. A total of 733 participants were included. All interventions consisted of transdermal testosterone, and the intervention period varied from 6 months to 1 year. The overall results ([Fig. 5](#F5){ref-type="fig"}) showed improved physical performance after TRT. Other studies that also showed improved physical performance after testosterone supplementation could not be included in the analysis because they only presented data in figures for a timed PPT \[[@B26]\] or gait speed \[[@B19]\] and did not provide exact measurements. Another study did not report outcomes for the functional assessment tests that were conducted, such as maximal reach, standing balance, fast walk, and chair rise \[[@B9]\], and hence, could not be included.

SUMMARY
=======

The overall analyses showed that TRT is not associated with increased muscle strength, whereas it does increase physical function. This is in accordance with previous findings \[[@B7][@B8][@B9]\]. However, as the number of studies included in some analyses was limited, these results are not generalizable to elderly men in general as a whole. Additionally, most of the reviewed RCTs were conducted in the United States or Europe, and there was no mention of the inclusion of participants from other ethnic backgrounds, such as Asians. Therefore, further studies are needed to investigate the effects of TRT on muscle strength and physical function in populations with a broader ethnic background.

Some difficulties were encountered during the review. For instance, when comparing results for muscle strength, some studies included exercise training and some did not. Moreover, some studies measured isokinetic muscle strength and some measured isometric muscle strength with different dynamometers, which made them difficult to compare. Additionally, the muscle strength evaluation protocols differed for each study. The lack of a standardized, validated exercise protocol to evaluate muscle strength made it difficult to compare the results and suggests that further studies are needed to develop a standardized protocol to be disseminated and widely used.

SEARCH STRATEGIES
=================

We performed 2 sets of searches, one as a rapid SR and an additional traditional SR, because the latest published SR included studies published up to April 9, 2016. The results for the rapid and traditional SRs and meta-analyses were reported following the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@B35]\] ([Fig. 6](#F6){ref-type="fig"}).

For the rapid SR, the PubMed Central, MEDLINE, and Embase databases were searched for studies published up to October 30, 2017. The initial search was conducted using the following keywords: elderly men aged at least 60 years (for participants), testosterone replacement (for intervention), placebo (for comparison), physical performance (for outcome), and SR (for study design) (see [Supplementary Table 1](#S1){ref-type="supplementary-material"} for the complete list of the search terms). We only included articles published in English. Studies were considered eligible for the rapid SR if they met the following inclusion criteria: 1) being a SR; 2) including elderly men at least 60 years of age; 3) reporting physical function, physical performance, and/or muscle strength; 4) having TRT as the major intervention; and 5) including a comparison with a placebo. Although we searched for healthy elderly men, we did not exclude studies if they included participants with hypogonadism, but studies of other specific diseases, such as diabetes mellitus and Parkinson disease, were excluded from the analysis. We included interventions that compared testosterone supplementation vs. placebo or other substances, such as growth hormone. As a result, 1 SR \[[@B13]\] was retrieved for assessment. The other 3 SRs were excluded because 2 \[[@B10][@B11]\] included inappropriate populations and one \[[@B12]\] had inappropriate outcomes. We then applied AMSTAR \[[@B36]\], a measurement tool for assessing the methodological quality of the retrieved SR, which gave a score of 4 out of 11 (see [Appendix 1](#APP1){ref-type="app"} for details).

For the additional traditional SR, as the retrieved SR used for the rapid SR included studies between January 1, 1950, and April 9, 2016, we searched for additional RCTs from January 1, 2015, to October 30, 2017 through the PubMed Central, MEDLINE, and Embase databases. We used the same search terms as were used for the rapid SR except for the study design, which was RCTs (see [Supplementary Table 2](#S2){ref-type="supplementary-material"} for a complete list of the search terms). After excluding studies that did not match our inclusion criteria, we included a total of 17 studies and added the 4 RCTs retrieved from the additional search. Subsequently, a total of 21 full-text articles were reviewed for the analysis and 3 studies were further excluded because their population \[[@B37][@B38]\] and outcome measures \[[@B39]\] did not meet our criteria. A total of 18 studies were included in the final analysis.

STATISTICAL ANALYSIS
====================

Statistical analyses were performed using STATA ver. 15.0 (StataCorp, College Station, TX, USA) using the *metan* command with a random effect. When outcome measurements were given in the same units or the units could be converted, weighted mean differences were calculated, whereas if outcome measurements were given in different, non-convertible units, standardized mean differences were calculated instead.
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###### Effects of testosterone on muscle strength and physical function

![](wjmh-36-110-i001)

  Study (year)                               Country       Type of intervention                                                                                                                                                        Intervention period   Primary outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcome
  ------------------------------------------ ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bakhshi et al \[[@B15]\] (2000)            US            Testosterone enanthate (100 mg weekly, intramuscular injections)                                                                                                            8 wk                  Functional independence measure, hand grip strength (dominant)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Geriatric Depression Scale - Short Form
  Borst et al \[[@B16]\] (2014)              US            Testosterone and placebo                                                                                                                                                    12 mo                 Prostate digital rectal examination and transrectal ultrasonography, 1-repetition maximum strength testing (leg press, knee flexion, knee extension, chest press, and triceps extension), grip strength, urinary symptoms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             N/A
  Brill et al \[[@B17]\] (2002)              US            Transdermal placebo or T patches (Androderm, two 2.5-mg patches applied at bedtime) and evening subcutaneous injections of saline or rhGH (Genotropin, 6.25 g/kg per day)   1--3 mo wash-out      Body composition, performance, mood, sexual function, bone turnover, and muscle gene expression                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Clague et al \[[@B18]\] (1999)             UK            Testosterone enanthate (200 mg intramuscular injections, at 2-wk intervals)                                                                                                 12 wk                 Muscle function                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Dias et al \[[@B19]\] (2016)               US            5 g of transdermal testosterone gel                                                                                                                                         12 mo                 BMD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Body composition; muscle strength; gait speed; sex hormone levels
  Emmelot-Vonk et al \[[@B20]\] (2008)       Netherlands   80 mg of oral testosterone undecanoate twice daily                                                                                                                          6 mo                  Functional mobility (Stanford Health Assessment Questionnaire, timed getup-and-go test, isometric handgrip strength, isometric leg extensor strength), cognitive function (8 different cognitive instruments), BMD of the hip and lumbar spine (dual-energy x-ray absorptiometry scanning), body composition (total body dual-energy x-ray absorptiometry and abdominal ultrasound of fat mass), metabolic risk factors (fasting plasma lipids, glucose, and insulin), quality of life (Short-Form Health 36 Survey and the Questions on Life Satisfaction Modules), and safety parameters (serum prostate-specific antigen level, ultrasonographic prostate volume, International Prostate Symptom score, serum levels of creatinine, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, hemoglobin, and hematocrit)   N/A
  Giannoulis et al \[[@B21]\] (2006)         UK            Fixed dose of 5 mg of testosterone through transdermal patches (testosterone and placebo rhGH)                                                                              6 mo                  Lean body mass, total body fat, mid-thigh muscle cross-section area, muscle strength, aerobic capacity, condition-specific quality of life (Age-Related Hormone Deficiency-Dependent Quality of Life questionnaire), and generic health status (36-Item Short-Form Health Survey)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Hildreth et al \[[@B22]\] (2013)           US            Transdermal testosterone gel (2 doses targeting either a lower \[400--550 ng/dL\] or higher \[600--1,000 ng/dL\] testosterone range)                                        12 mo                 Functional performance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Strength and body composition
  Kenny et al \[[@B23]\] (2001)              US            Transdermal testosterone supplementation                                                                                                                                    12 mo                 Sex hormone levels, calcium-regulating hormone levels, BMD, bone markers, frailty evaluation, strength measures, multiple physical performance Ameasures, and body composition were assessed; a prostate examination was performed; and hemoglobin and cholesterol levels were checked                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Kenny et al \[[@B24]\] (2010)              US            5 mg/d of testosterone gel                                                                                                                                                  12 mo                 BMD of hip, lumbar spine, and mid-radius; body composition; sex hormones, calcium-regulating hormones; bone turnover markers; strength; physical performance; and safety parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   N/A
  Ly et al \[[@B9]\] (2001)                  Australia     Application of 70 mg of dihydrotestosterone with a derma gel daily                                                                                                          3 mo                  Muscular strength                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Muscular function (gait, balance, mobility), body composition, reproductive hormones, hematopoiesis, prostate size and prostate-specific antigen, and vascular reactivity
  Nair et al \[[@B25]\] (2006)               US            Transdermal testosterone patch (5 mg per day; D-TRANS, Alza)                                                                                                                24 mo                 Physical performance, peak aerobic capacity, body composition, BMD, and levels of plasma insulin and glucose after an overnight fast                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Body weight, the proportion of body fat, the insulin-sensitivity index, quality of life, levels of various hormones, and levels of alkaline phosphatase, alanine aminotransferase, aspartate transferase, and hemoglobin, and adverse events
  Page et al \[[@B26]\] (2005)               US            Testosterone enanthate, 200 mg intramuscularly every 2 wk, with placebo pills daily (testosterone-only)                                                                     36 mo                 Timed physical performance, grip strength, lower extremity strength, body composition (by dual-energy x-ray absorptiometry), fasting cholesterol profiles, and hormones                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Sih et al \[[@B7]\] (1997)                 US            200 mg (1 mL) of testosterone cypionate intramuscularly every 14--17 d (n=17)                                                                                               12 mo                 Strength (hand grip), hemoglobin, prostate-specific antigen, leptin, cognition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Alanine aminotransferase, gamma-glutamyltransferase, lactate dehydrogenase, blood pressure, cholesterol, 1,25 vitamin D, body mass index, body fat
  Snyder et al \[[@B2]\] (2016)              US            5 g of a transdermal testosterone gel                                                                                                                                       12 mo                 The percentage of men who increased the distance walked in the 6-min walk test by at least 50 m                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The percentage of men whose score on the physical-function domain (PF-10) of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) increased by at least 8 points and changes from baseline in the 6-min walking distance and PF-10 score.
  Srinivas-Shankar et al \[[@B27]\] (2010)   New Zealand   Transdermal testosterone (50 mg/d)                                                                                                                                          6 mo                  Isometric knee extension peak torque and isokinetic knee extension peak torque                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Isometric knee flexion peak torque, isokinetic knee flexion peak torque, physical function tests, body composition, and quality of life. All outcome assessments were carried out by a single assessor at baseline and at 6 months (end of treatment).
  Storer et al \[[@B14]\] (2017)             US            7.5 g of 1% testosterone                                                                                                                                                    36 mo                 Muscle strength, power, and fatigability, muscle strength (1-RM), muscle power (leg-press, chest-press), muscle fatigability, stair-climb power, lean body mass, hormone assays                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       N/A
  Wittert et al \[[@B8]\] (2003)             Australia     Standard dose (80 mg twice daily) of testosterone undecanoate (Andriol; Organon, Oss, The Netherlands)                                                                      1 y                   Body composition, muscle strength, hormones, and safety parameters (hematocrit, prostate-specific antigen, urine flow, systolic and diastolic blood pressure, high-density lipoprotein, low-density lipoprotein, total cholesterol, triglycerides)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

rhGH: recombinant human growth hormone, BMD: bone mineral density, N/A: not applicable.
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